CME/CE

Faculty: Linda Bradley, MD Faculty: Obianuju Sandra Madueke-Laveaux, MD, MPH Faculty: Lauren R. Kornegay This dynamic symposium will guide clinicians through a modern, patient-centered approach to endometriosis care. Faculty will explore how early diagnosis can improve physical and psychosocial outcomes, examine tools to advance equity and shared decision-making, and evaluate the latest evidence f...

Faculty: Gideon Hirschfield, MB, BChir, PhD Faculty: Marlyn Mayo, MD This WHAV 2025 session examines primary biliary cholangitis (PBC), a chronic autoimmune liver disease that predominantly affects women and often goes unrecognized. Tailored for clinicians who play a key role in identifying symptoms and initiating referrals, the session outlines diagnostic criteria—including AMA positivity and ele...

Host: Martin J. Abrahamson, MD, FACP, FRCP Guest: Stefano Del Prato, MD Guest: Linong Ji, MD On-demand webcast with expert faculty presentation highlighting key studies in diabetes from the 2025 American Diabetes Association and European Association for the Study of Diabetes annual meetings.

Faculty: Kirk Campbell, MD Guest: Joshua Albright Guest: Titilayo Ilori, MBBS Host : Kirk Campbell, University of Pennsylvania Guests : Joshua Albright, Kidney Health Advocate & Titilayo Ilori, Boston University Join our host Dr. Kirk Campbell (University of Pennsylvania) as he speaks with Dr. Titilayo Ilori (Boston University) and patient advocate Joshua Albright about APOL1 screening and ear...

Faculty: Kirk Campbell, MD Faculty: Bessie Young, MPH, MD Welcome to KDIGO Conversations in Nephrology: Burden and Pathophysiology of APOL1 Kidney Disease! Join our host Dr. Kirk Campbell (University of Pennsylvania) as he speaks with Dr. Bessie Young (University of Washington) about the discovery, impact, and future of APOL1 kidney disease. This episode explores the significant burden of kidney d...

Faculty: Iacopo Olivotto, MD Faculty: Ahmad Masri, MD, MS Faculty: Pablo Garcia-Pavia, MD, PhD Faculty: Fabian Knebel, MD, PhD Faculty: Caroline Coats, MD Hypertrophic cardiomyopathy (HCM) management is being transformed by advances in diagnostics and the emergence of targeted therapies. In this program, leading international experts review challenges in early recognition, the evolving role of bet...

Faculty: Kirk Campbell, MD Guest: Joshua Albright Guest: Titilayo Ilori, MBBS Host : Kirk Campbell, University of Pennsylvania Guests : Joshua Albright, Kidney Health Advocate & Titilayo Ilori, Boston University Join our host Dr. Kirk Campbell (University of Pennsylvania) as he speaks with Dr. Titilayo Ilori (Boston University) and patient advocate Joshua Albright about APOL1 screening and ear...

Faculty: Kirk Campbell, MD Faculty: Bessie Young, MPH, MD Welcome to KDIGO Conversations in Nephrology: Burden and Pathophysiology of APOL1 Kidney Disease! Join our host Dr. Kirk Campbell (University of Pennsylvania) as he speaks with Dr. Bessie Young (University of Washington) about the discovery, impact, and future of APOL1 kidney disease. This episode explores the significant burden of kidney d...

Faculty: Iacopo Olivotto, MD Faculty: Ahmad Masri, MD, MS Faculty: Pablo Garcia-Pavia, MD, PhD Faculty: Fabian Knebel, MD, PhD Faculty: Caroline Coats, MD Hypertrophic cardiomyopathy (HCM) management is being transformed by advances in diagnostics and the emergence of targeted therapies. In this program, leading international experts review challenges in early recognition, the evolving role of bet...

Faculty: Brooks D. Cash, MD, AGAF, FACG, FACP, FASGE Faculty: Kimberly D. Orleck, PA-C Presented at the 21st Annual Women’s Health Annual Visit (WHAV 2025), this session reviews strategies for diagnosing and treating irritable bowel syndrome (IBS), with a focus on distinguishing IBS-C from IBS-D. Faculty explore the burden of disease, stigma, and the importance of a positive diagnostic strategy us...

Faculty: Brooks D. Cash, MD, AGAF, FACG, FACP, FASGE Faculty: Kimberly D. Orleck, PA-C Presented at the 21st Annual Women’s Health Annual Visit (WHAV 2025), this session reviews strategies for diagnosing and treating irritable bowel syndrome (IBS), with a focus on distinguishing IBS-C from IBS-D. Faculty explore the burden of disease, stigma, and the importance of a positive diagnostic strategy us...

Faculty: Alison Kole Faculty: Ghada Bourjeily, MD, FCCP Faculty: Rashmi Nisha Aurora, MD Faculty: Audrey Wells, MD This WHAV 2025 session addresses obstructive sleep apnea (OSA) in women, highlighting how phenotype and risk factors shift across life stages. Experts discuss how varying phenotypes contribute to delayed diagnosis and review screening tools, referral strategies, evidence linking OSA t...

Faculty: Alison Kole Faculty: Ghada Bourjeily, MD, FCCP Faculty: Rashmi Nisha Aurora, MD Faculty: Audrey Wells, MD This WHAV 2025 session addresses obstructive sleep apnea (OSA) in women, highlighting how phenotype and risk factors shift across life stages. Experts discuss how varying phenotypes contribute to delayed diagnosis and review screening tools, referral strategies, evidence linking OSA t...

Faculty: Komal Jhaveri, MD, FACP Faculty: Kevin Kalinsky MD, MS The PI3K-AKT-mTOR pathway is a crucial signaling network dysregulated in many cancers, promoting cell survival, growth, and proliferation, and often implicated in resistance to cancer therapies. Inhibition of this pathway by PI3K inhibitors disrupts a complex network of cellular processes that contribute to breast cancer, markedly red...

Faculty: Komal Jhaveri, MD, FACP Faculty: Kevin Kalinsky MD, MS The PI3K-AKT-mTOR pathway is a crucial signaling network dysregulated in many cancers, promoting cell survival, growth, and proliferation, and often implicated in resistance to cancer therapies. Inhibition of this pathway by PI3K inhibitors disrupts a complex network of cellular processes that contribute to breast cancer, markedly red...

Faculty: Komal Jhaveri, MD, FACP Faculty: Kevin Kalinsky MD, MS The PI3K-AKT-mTOR pathway is a crucial signaling network dysregulated in many cancers, promoting cell survival, growth, and proliferation, and often implicated in resistance to cancer therapies. Inhibition of this pathway by PI3K inhibitors disrupts a complex network of cellular processes that contribute to breast cancer, markedly red...

Faculty: Komal Jhaveri, MD, FACP Faculty: Kevin Kalinsky MD, MS The PI3K-AKT-mTOR pathway is a crucial signaling network dysregulated in many cancers, promoting cell survival, growth, and proliferation, and often implicated in resistance to cancer therapies. Inhibition of this pathway by PI3K inhibitors disrupts a complex network of cellular processes that contribute to breast cancer, markedly red...

Faculty: Komal Jhaveri, MD, FACP Faculty: Kevin Kalinsky MD, MS The PI3K-AKT-mTOR pathway is a crucial signaling network dysregulated in many cancers, promoting cell survival, growth, and proliferation, and often implicated in resistance to cancer therapies. Inhibition of this pathway by PI3K inhibitors disrupts a complex network of cellular processes that contribute to breast cancer, markedly red...

Faculty: Komal Jhaveri, MD, FACP Faculty: Kevin Kalinsky MD, MS The PI3K-AKT-mTOR pathway is a crucial signaling network dysregulated in many cancers, promoting cell survival, growth, and proliferation, and often implicated in resistance to cancer therapies. Inhibition of this pathway by PI3K inhibitors disrupts a complex network of cellular processes that contribute to breast cancer, markedly red...

Faculty: Komal Jhaveri, MD, FACP Faculty: Kevin Kalinsky MD, MS The PI3K-AKT-mTOR pathway is a crucial signaling network dysregulated in many cancers, promoting cell survival, growth, and proliferation, and often implicated in resistance to cancer therapies. Inhibition of this pathway by PI3K inhibitors disrupts a complex network of cellular processes that contribute to breast cancer, markedly red...

Faculty: Kevin Kalinsky MD, MS The PI3K-AKT-mTOR pathway is a crucial signaling network dysregulated in many cancers, promoting cell survival, growth, and proliferation, and often implicated in resistance to cancer therapies. Inhibition of this pathway by PI3K inhibitors disrupts a complex network of cellular processes that contribute to breast cancer, markedly reducing cell proliferation, promoti...

Faculty: Komal Jhaveri, MD, FACP Faculty: Kevin Kalinsky MD, MS The PI3K-AKT-mTOR pathway is a crucial signaling network dysregulated in many cancers, promoting cell survival, growth, and proliferation, and often implicated in resistance to cancer therapies. Inhibition of this pathway by PI3K inhibitors disrupts a complex network of cellular processes that contribute to breast cancer, markedly red...

Faculty: Komal Jhaveri, MD, FACP Faculty: Kevin Kalinsky MD, MS The PI3K-AKT-mTOR pathway is a crucial signaling network dysregulated in many cancers, promoting cell survival, growth, and proliferation, and often implicated in resistance to cancer therapies. Inhibition of this pathway by PI3K inhibitors disrupts a complex network of cellular processes that contribute to breast cancer, markedly red...

Faculty: Komal Jhaveri, MD, FACP Faculty: Kevin Kalinsky MD, MS The PI3K-AKT-mTOR pathway is a crucial signaling network dysregulated in many cancers, promoting cell survival, growth, and proliferation, and often implicated in resistance to cancer therapies. Inhibition of this pathway by PI3K inhibitors disrupts a complex network of cellular processes that contribute to breast cancer, markedly red...

Faculty: Komal Jhaveri, MD, FACP Faculty: Kevin Kalinsky MD, MS The PI3K-AKT-mTOR pathway is a crucial signaling network dysregulated in many cancers, promoting cell survival, growth, and proliferation, and often implicated in resistance to cancer therapies. Inhibition of this pathway by PI3K inhibitors disrupts a complex network of cellular processes that contribute to breast cancer, markedly red...